CSTL — CASTLE BIOSCIENCES INC

Nasdaq · Health Care · Health Care Providers & Services · CIK 1447362 ·
Last close
$19.69
Market Cap
$597.20M
52W High
$30.50
52W Low
$17.72
ADV30
437,520
Next earnings
2026-08-03
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 83,679,000 63,146,000 -18,407,000 -14,522,000 547,805,000 63,764,000 86,389,000
Dec 2025 87,010,000 68,695,000 -3,827,000 -2,332,000 578,556,000 116,729,000 107,683,000
Sep 2025 83,043,000 64,339,000 -6,804,000 -501,000 562,786,000 85,556,000 95,740,000
Jun 2025 86,188,000 68,562,000 -4,251,000 4,523,000 544,729,000 82,233,000 89,353,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$64,347,000
Investing CF
$-60,367,000
Financing CF
$-6,960,000
CapEx
$-36,021,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.85
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-224,284,000
Inventory
$10,254,000
Receivables
$43,382,000
ST Investments
$182,776,000
EBIT TTM
$-29,428,000
Pretax Income TTM
$-29,514,000
Interest Exp TTM
$86,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$339,920,000
EBITDA
$-18,353,000
Free Cash Flow
$12,890,500
Enterprise Value
$372,235,744
Total Cash
$261,684,992
Total Debt
$36,724,000
Shares Out
30,329,952
Trailing EPS
$-0.42
Book Value
$15.23
ROE
-2.8%
ROA
-4.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 344,229,000 -42,810,000 -24,158,000 578,556,000 107,683,000 64,347,000
Dec 2024 332,069,000 8,670,000 18,245,000 531,235,000 75,400,000 64,866,000
Dec 2023 219,788,000 -67,977,000 -57,466,000 453,340,000 62,071,000 -5,626,000
Dec 2022 137,039,000 -91,142,000 -67,138,000 447,329,000 48,179,000 -41,655,000

TTM Snapshot

Revenues TTM
$208,981,000
NetIncome TTM
$-30,025,000
OpCashFlow TTM
$0
Assets (Latest)
$531,235,000
Forward EPS
$-0.90

Peers — same industry

TickerNameMarket CapLastDaily %
SRTA Strata Critical Medical, Inc. $531.27M $6.14
EHAB Enhabit, Inc. $706.91M $13.80
FLGT Fulgent Genetics, Inc. $501.84M $17.67
TOI Oncology Institute, Inc. $458.92M $4.59
LMRI Lumexa Imaging Holdings, Inc. $784.98M $8.17

News headlines (Yahoo Finance, 1h cache)

How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets
2026-05-24 16:13 · Yahoo
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-13 11:00 · Yahoo
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
2026-05-12 11:00 · Yahoo
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary
2026-05-07 00:22 · Yahoo
Castle Biosciences Q1 Earnings Call Highlights
2026-05-07 00:07 · Yahoo
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
2026-05-06 22:30 · Yahoo
Castle Biosciences Reports First Quarter 2026 Results
2026-05-06 20:05 · Yahoo
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
2026-05-06 16:06 · Yahoo
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
2026-05-06 16:01 · Yahoo
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
2026-05-06 15:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.